UBS AM’s Vanda Pharmaceuticals VNDA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.95K Buy
+397
New +$2.13K ﹤0.01% 4048
2025
Q3
– Sell
-17,565
Closed -$82.9K – 2619
2025
Q2
$82.9K Buy
+17,565
New +$76.8K ﹤0.01% 2595
2023
Q4
– Sell
-71,000
Closed -$307K – 2606
2023
Q3
$307K Sell
71,000
-12,309
-15% -$68.4K ﹤0.01% 2428
2023
Q2
$566K Hold
83,309
– – ﹤0.01% 2274
2023
Q1
$566K Buy
83,309
+23,159
+39% +$163K ﹤0.01% 2274
2022
Q4
$445K Hold
60,150
– – ﹤0.01% 2220
2022
Q3
$594K Hold
60,150
– – ﹤0.01% 2266
2022
Q2
$656K Hold
60,150
– – ﹤0.01% 2172
2022
Q1
$680K Hold
60,150
– – ﹤0.01% 2335
2021
Q4
$944K Hold
60,150
– – ﹤0.01% 2242
2021
Q3
$1.03M Buy
60,150
+12,309
+26% +$216K ﹤0.01% 2148
2021
Q2
$1.03M Buy
47,841
+6,582
+16% +$118K ﹤0.01% 2205
2021
Q1
$620K Sell
41,259
-6,591
-14% -$107K ﹤0.01% 2308
2020
Q4
$629K Hold
47,850
– – ﹤0.01% 2208
2020
Q3
$462K Hold
47,850
– – ﹤0.01% 2180
2020
Q2
$547K Buy
47,850
+2,814
+6% +$31.9K ﹤0.01% 2084
2020
Q1
$467K Buy
45,036
+5,293
+13% +$65.6K ﹤0.01% 2002
2019
Q4
$652K Sell
39,743
-4,913
-11% -$74.3K ﹤0.01% 2121
2019
Q3
$593K Buy
44,656
+10,329
+30% +$144K ﹤0.01% 2199
2019
Q2
$484K Buy
34,327
+16,171
+89% +$257K ﹤0.01% 2226
2019
Q1
$334K Buy
18,156
+4,732
+35% +$108K ﹤0.01% 2270
2018
Q4
$351K Buy
+13,424
New +$316K ﹤0.01% 2139
2016
Q4
– Sell
-16,300
Closed -$271K – 2666
2016
Q3
$271K Hold
16,300
– – ﹤0.01% 2320
2016
Q2
$182K Buy
16,300
+1,600
+11% +$15.5K ﹤0.01% 2472
2016
Q1
$123K Sell
14,700
-15,700
-52% -$129K ﹤0.01% 2540
2015
Q4
$283K Sell
30,400
-1,400
-4% -$14K ﹤0.01% 2366
2015
Q3
$358K Buy
31,800
+1,900
+6% +$23.2K ﹤0.01% 2193
2015
Q2
$379K Buy
29,900
+1,400
+5% +$15.1K ﹤0.01% 2218
2015
Q1
$265K Buy
28,500
+1,000
+4% +$11.3K ﹤0.01% 2340
2014
Q4
$394K Buy
27,500
+15,600
+131% +$185K ﹤0.01% 2067
2014
Q3
$124K Hold
11,900
– – ﹤0.01% 2476
2014
Q2
$193K Buy
+11,900
New +$158K ﹤0.01% 2424

Other funds holding VNDA

UBS AM's VNDA Position: Q3 2026 in Review

UBS AM opened a new position in Vanda Pharmaceuticals (VNDA) in Q3 2026: 397 shares worth $1.95K. The stake represents ﹤0.01% of the portfolio and ranks #4048 among its holdings. This is a return to the name: UBS AM previously reported a position in VNDA as recently as Q2 2025.

UBS AM first reported a position in VNDA in Q2 2014 and has held it in 32 quarters since. The position peaked at $1.03M in Q3 2021. 128 funds tracked by Wall St. Rank hold VNDA as of Q3 2026.

  • UBS AM held 397 shares of Vanda Pharmaceuticals worth $1.95K as of Q3 2026.
  • Vanda Pharmaceuticals was a new UBS AM position in Q3 2026.
  • Vanda Pharmaceuticals made up ﹤0.01% of UBS AM's portfolio in Q3 2026, its #4048 holding.
  • UBS AM first reported a position in Vanda Pharmaceuticals in Q2 2014 and has held it in 32 quarters since.
  • UBS AM's Vanda Pharmaceuticals position peaked at $1.03M in Q3 2021.
  • 128 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2026.

Based on UBS AM's 13F filing for Q3 2026, filed 16 Nov 2026.